Bio-Connect

Mouse anti Neu-Oncogen (C-erb B2)

Research Use Only
MUB1320P-CE/IVD
Nordic-MUbio
ApplicationsElectron Microscopy, Flow Cytometry, ImmunoFluorescence, ImmunoPrecipitation, Western Blot, ImmunoHistoChemistry
Product group Antibodies
ReactivityHuman
€ 226,00
0.1 mg
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    Nordic-MUbio
  • Product Name
    Mouse anti Neu-Oncogen (C-erb B2)
  • Delivery Days Customer
    7
  • Applications
    Electron Microscopy, Flow Cytometry, ImmunoFluorescence, ImmunoPrecipitation, Western Blot, ImmunoHistoChemistry
  • Applications Supplier
    Electron microscopy;Flow Cytometry;Immunofluorescence;Immunohistochemistry (frozen);Immunohistochemistry (paraffin);Immunoprecipitation;Western Blotting
  • Category Supplier
    Primary antibodies
  • Certification
    Research Use Only
  • Clone ID
    9G6
  • Host
    Mouse
  • Isotype
    IgG1
  • Source
    9G6 is a mouse monoclonal IgG1 antibody derived by fusion of SP2/0 mouse myeloma cells with spleen cells from a BALB/c mouse immunized with a synthetic peptide from the C-terminus of Human c-erbB-2/c-neu protein.
  • Reactivity
    Human
  • Reactivity Supplier
    Human
  • Storage Instruction
    The antibody is shipped at ambient temperature and may be stored at +4°C. For prolonged storage prepare appropriate aliquots and store at or below -20°C. Prior to use, an aliquot is thawed slowly in the dark at ambient temperature, spun down again and used to prepare working dilutions by adding sterile phosphate buffered saline (PBS, pH 7.2). Repeated thawing and freezing should be avoided. Working dilutions should be stored at +4°C, not refrozen, and preferably used the same day. If a slight ...
  • UNSPSC
    12352203

References

  • 1. Van de Vijver, M.J. Peterse, J.L. Mooi, W.J. Wisman, P. Lomans, J. Dalesio, O. and Nusse, R. (1988). Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med. 319, 1239-45.